Literature DB >> 29960214

Activity enhancement of selective antitumoral selenodiazoles formulated with poloxamine micelles.

Amaia Úriz1, Carmen Sanmartín2, Daniel Plano2, Raquel de Melo Barbosa3, Cécile A Dreiss4, Gustavo González-Gaitano5.   

Abstract

Selenium (Se) incorporated into organic frameworks has demonstrated anticancer activity against several cancer types. One of the drawbacks of most of these constructs is their poor solubility and bioavailability, which can be overcome with the use of suitable nanocarriers. We have synthesized a series of 5-substituted amide selenodiazoles, based on the parent structure of ebselen, an organoselenium drug with proven cytoprotective activity, and solubilized them in polymeric micelles of poloxamines, poly(ethylene oxide)-poly(propylene oxide) X-shaped tetrablock-copolymers. Scattering methods (SANS and DLS) were employed to characterize the micellar nanocarriers. MTT biological evaluation highlights the selectivity of the Se-compounds towards cancer cells, with MCF-7 standing as the most responsive line. The alkylation of the heterocycle with a 12-carbon hydrophobic tail displays the highest activity, showing a 100-fold increase with respect to ebselen. This compound also exhibits the greatest increase in solubility in poloxamine micelles, overall resulting in a one-fold increase in activity with respect to the non-formulated form, making it a hit compound for further optimization.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Ebselen; Poloxamines; Polymeric micelles; Selenium; Tetronics

Mesh:

Substances:

Year:  2018        PMID: 29960214     DOI: 10.1016/j.colsurfb.2018.06.009

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  1 in total

1.  New Formulation of a Methylseleno-Aspirin Analog with Anticancer Activity towards Colon Cancer.

Authors:  Ana Carolina Ruberte; Gustavo González-Gaitano; Arun K Sharma; Carlos Aydillo; Ignacio Encío; Carmen Sanmartín; Daniel Plano
Journal:  Int J Mol Sci       Date:  2020-11-27       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.